• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Here Are the Real Victims of Pakistan’s War on the Taliban
An elderly displaced man carries a sack of rations on his shoulder. The Pakistan Army has distributed 30,000 ration packs of 110 kg each. Credit: Ashfaq Yusufzai/IPSBy Ashfaq YusufzaiPESHAWAR, Pakistan, Jul 1 2014 (IPS) Three days ago, Rameela Bibi was the mother of a month-old baby boy. He died in her arms on Jun. 28, of a chest infection that he contracted when the family fled their home in Pakistan’s North Waziristan Agency, where a full-scale military offensive against the Taliban has forced nearly half a million people to flee. Weeping uncontrollable, Bibi struggles to recount her story. “My son was born on Jul. 2...
Source: IPS Inter Press Service - Health - July 1, 2014 Category: Global & Universal Authors: Ashfaq Yusufzai Tags: Aid Armed Conflicts Asia-Pacific Development & Aid Economy & Trade Editors' Choice Environment Featured Food & Agriculture Gender Headlines Health Human Rights Humanitarian Emergencies Migration & Refugees Population Povert Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news